期刊文献+

高效液相色谱法测定人血浆中莫西沙星浓度 被引量:3

Determination of Moxifloxaxin Concentration in Plasma by HPLC
原文传递
导出
摘要 目的:建立以高效液相色谱法测定人血浆中莫西沙星浓度的方法。方法:以Kromasil C_8柱为固定相,0.05mol·L^(-1)磷酸二氢钾缓冲液:甲醇:乙腈(65:15:20)为流动相,调节pH至3.0,流速1 ml·min^(-1),柱温30℃,紫外检测波长296nm,进样量20μl。沉淀剂选用8%高氯酸溶液,以峰面积外标法定量。结果:莫西沙星保留时间为6.2min,线性范围0.08~4.80mg·L^(-1),最低定量限为0.08mg·L^(-1);方法平均回收率为95.20%~100.85%,绝对回收率为79.98%~91.83%;高、中、低系列浓度日内RSD为4.69%~5.23%,日间RSD为6.08%~7.36%;样品在低温冷冻条件下至少可稳定保存28d。结论:本法简便、快速,灵敏度高,重复性好,适用于临床血药浓度测定及药动学研究。 Objective: To establish an HPLC method for determination of moxifloxacin concentration in human plasma and to study its pharmacokinetics. Method: The separation was performed on a Kromasil C8 column with mobile phase consisted of 65% 0.05mol. L^-1 potassiun dihydrogen phosphorate buffer solution (containing 1% triethylamine, pH adjusted to 3.0), 15% methanol and 20% acetonitrile. The flow rate was 1.0 ml.min^-1 and the detection wavelength was at 296 nm. The column temperature was 30℃ and injection volume was 20ul. 8% perchloric acid was chosen as precipitator. External standard method was used. Result: The retention time of moxifloxacin was about 6.2 min. The calibration curve was linear within the concentration range of 0.08 - 4.80 mg·L^-1. The limit of quantitation (LOQ) was 0.08 mg·L^-1. The recovery of methodology was 95.20% - 100.85% ; and the absolute recovery was 79.98% - 91.83%. RSD for within day precision and between day precision were 4.69% - 5.23% and 6.08% - 7.36% %, respectively. The sample under frozen condition was stable at least within 28 days. Conclusion: The established HPLC method is simple, sensitive and accurate. It could be used for the determination of moxiflocacin concentration in plasma and its pharmacokinetics study.
出处 《中国药师》 CAS 2009年第11期1537-1539,共3页 China Pharmacist
基金 深圳市科技计划(医疗卫生类)项目(项目编号:200703224)
关键词 莫西沙星 高效液相色谱法 血药浓度 Moxicifloxacin Plasma concentration HPLC
  • 相关文献

参考文献9

  • 1Julia A, Balfour B, Wiseman LR. Moxifloxacin[J]. Drugs, 1999,57(3) : 363 -373.
  • 2徐西琳,余爱荣.莫西沙星与左氧氟沙星治疗下呼吸道感染比较[J].药物流行病学杂志,2007,16(3):136-138. 被引量:8
  • 3Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-metnoxy quinolone, administered to healthy subjects [ J ]. Antimicrob Agents Chemother, 1998, 42 (8) :2060-2065.
  • 4Stass H, Kubitza D, Schuhly U, et al. Pharmacokinefics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration [ J ]. Clinical Pharmacokinetics, 2001,40 ( S1 ) : 1-9.
  • 5Laban-Djurdjevi O, Jeliki O-Stankov M, Djurdjevi OP. Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci,2006, 844( 1 ) :104- 111.
  • 6Tatar US. High-performance liquid chromatography assay for moxitloxacin: pharmacokinetics in human plasma [ J]. J Pharm Biomed Anal,2007, 43( 1 ) : 320-324.
  • 7Schulte S, Ackermann T, Bertram N, et al. Determination of the newer quinolones levofloxacin and moxitloxacin in plasma by high-performance liquid chro- matography with fluorescence detection [ J ]. J Chromatogr Sci, 2006,44 ( 4 ) : 205-258.
  • 8Lemoine T, Breilh D, Ducint D, et al. Determination of moxitloxacin( BAY 12-8039) in plasma and lung tissue by high performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge[J] . J Chromatogr B, 2000, 742(2) :247-254.
  • 9Karthick V, Michael GB, James TS. Determination of moxifloxacin in human plasma by liquid chromatography electro spray ionization tandem mass spectrometry[ J]. J Pharm Biomed Anal, 2002 ,30(4) :961-968.

二级参考文献5

  • 1董亮,王树诚,孙恩华,于钦凤,张琦,吴大玮.莫西沙星治疗慢性支气管炎急性加重的临床疗效及体外抗菌活性的研究[J].中国药学杂志,2005,40(9):702-704. 被引量:14
  • 2HunterPA.拜复乐-呼吸道感染门诊治疗专栏.中国实用内科杂志,2002,22(10):635-638.
  • 3Starakis I,Gogos CA,Bassaris H.Five-day moxifloxaction therapy compared with 7-day co-amoxiclav therapy for the treatmemt of acute exacerbation of chroni bronchitis[J].Int J Antimicrob Agents,2004,23:129-137
  • 4Banman BJA,Wiseman LR.Moxifolxacin[J].J Drugs,1999,57(3):363
  • 5Baz MN Jannetti W,Villanueva C,et al.The efficacy and tolerability of moxifloxacin compared with trovafloxacin in the treatmen of acute sinusitis[J].Today Ther Trends,1999,17(4):303

共引文献7

同被引文献35

  • 1张翠莲,Charles H.Nightingale,David P.Nicolau.反相HPLC测定培养基中莫西沙星含量的方法学研究[J].中国药学杂志,2004,39(9):699-701. 被引量:11
  • 2张吟,陈一农,陈文发.固相萃取-高效液相色谱法测定人血清中莫西沙星浓度[J].中国医院药学杂志,2007,27(4):481-483. 被引量:24
  • 3Julia A,Balfour B,Wiseman LR.Moxifloxacin[J].Drugs,1999,57(3):363-373.
  • 4Gillian MK,Lesley JS.Moxifloxacin:a review of its use in the management of bacterial infections[J].Drugs,2004,64 (20):2347-2377.
  • 5Krasemann C,Meyer J,Tillotson G.Evaluation of the clinical microbiology profile of moxifloxacin[J].Clon Infect Dis,2001,32 (Suppl 1):51-63.
  • 6Stass H,Dalhoff A,Kubitza D,et al.Pharmacokinetics,Safety,and Tolerability of Ascending Single Doses of Moxifloxacin,a New 8-Methoxy Quinolone,Administered to Healthy Subjects[J].Antimicrobial Agents and Chemotherapy,1998,42(8):2060-2065.
  • 7Stass H,Kubitza D,Schuhly,et al.Pharmacokinetics,Safety and Tolerability of Moxifloxacin,a Novel 8-Methoxyfluoroquinolone,after Repeated Oral Administration[J].Clinical Pharmacokinetics,2001,40 (S1):1-9.
  • 8Sullivan JT,Woodruff M,Lettieri J,et al.Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039),a New Enantiomerically Pure 8-Methoxy Quinolone[J].Antimicrob Agents Chemother,1999,43 (11):2793-2797.
  • 9Sullivan JT,Lettieri JT,Liu P,et al.The influence of age and gender on the pharmacokinetics of moxifloxacin[J].Clinical Pharmacokinetics,2001,40 (sup-pl 1):11-18.
  • 10Lettieri J,Vargas R,Agarwal V,et al.Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers[J].Clin Pharmacokinet,2001,40 (Suppl 1):19-25.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部